Cancer drug spurs blood pressure

Depressing scenario: You have cancer. You get the best high-tech drug. The drug gives you a heart attack.

It's increasingly apparent that some of our most-lauded new oncology agents carry pretty serious baggage. Take Sutent, a Pfizer drug that's one of the tyrosine kinase inhibitors that target signaling molecules inside cancer cells. A new study in the New England Journal of Medicine shows that it pushed blood pressure up by 15 to 25 percent in some kidney-cancer patients; last month, The Lancet published research indicating that stomach cancer patients using Sutent were more likely to develop heart failure, hypertension, and even heart attack.

Sutent isn't alone. Novartis' Gleevec was linked last year to heart failure in leukemia patients. Another new study, this time of Bristol-Myers Squibb's leukemia drug Sprycel, showed that one-quarter of patients had to stop treatment because of lung problems.

Of course, cancer has its own side effects, and these drugs are popular because they're effective against the disease. Plus, researchers say that most of the side effects can be managed; in Sutent's case, blood pressure drugs and other cardiac treatments are in order. But patients and doctors have to be on the lookout. And this is why drug makers have to be up front about adverse events--and why post-marketing research is always a good idea.

- here's the article from U.S. News and World Report
- read about last month's Sutent study
- get info about the Sprycel study from the Financial Times

Related Articles:
Sutent tops kidney-cancer drug scrips. Report
FDA approves Pfizer's Sutent for cancer. Report
Re-engineered Gleevec eliminates a side effect. Report
Researchers say Gleevec linked to heart damage. Report
FDA committee recommends Sprycel for leukemia. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.